Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert Ho

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Endocrinology|March 21, 2020
Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?Masaaki Waragai, Gilbert Ho, Yoshiki Takamatsu, et al.
Current Alzheimer Research|January 5, 2018
Potential Application of Centrifuges to Protect the CNS in Space and on EarthMakoto Hashimoto, Gilbert Ho, Yuka Shimizu, et al.
Journal of Alzheimer'S Disease : JAD|April 5, 2021
Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer's DiseaseMakoto Hashimoto, Gilbert Ho, Shuei Sugama, et al.
Drug Discovery Today|May 11, 2018
Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseasesMasaaki Waragai, Gilbert Ho, Yoshiki Takamatsu, et al.
NPJ Parkinson'S Disease|June 27, 2017
Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseasesYoshiki Takamatsu, Gilbert Ho, Wakako Koike, et al.
Neuroscience Letters|August 28, 2007
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's diseaseMasaaki Waragai, Masaaki Nakai, Jianshe Wei, et al.
Frontiers in Sports and Active Living|May 24, 2024
The effectiveness of video-based exercise training program for people with intellectual disability: a multicenter studyRachel Kwan, Grace Szeto, Ester Ho, et al.
Expert Review of Neurotherapeutics|July 31, 2019
Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease?Gilbert Ho, Yoshiki Takamatsu, Masaaki Waragai, et al.
Nature Medicine|April 27, 2005
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseMark H Tuszynski, Leon Thal, Mary Pay, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Frontiers in Endocrinology|March 21, 2020
Adiponectin Paradox in Alzheimer's Disease; Relevance to Amyloidogenic Evolvability?Masaaki Waragai, Gilbert Ho, Yoshiki Takamatsu, et al.
Current Alzheimer Research|January 5, 2018
Potential Application of Centrifuges to Protect the CNS in Space and on EarthMakoto Hashimoto, Gilbert Ho, Yuka Shimizu, et al.
Journal of Alzheimer'S Disease : JAD|April 5, 2021
Possible Role of Activin in the Adiponectin Paradox-Induced Progress of Alzheimer's DiseaseMakoto Hashimoto, Gilbert Ho, Shuei Sugama, et al.
Drug Discovery Today|May 11, 2018
Dual-therapy strategy for modification of adiponectin receptor signaling in aging-associated chronic diseasesMasaaki Waragai, Gilbert Ho, Yoshiki Takamatsu, et al.
NPJ Parkinson'S Disease|June 27, 2017
Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseasesYoshiki Takamatsu, Gilbert Ho, Wakako Koike, et al.
Neuroscience Letters|August 28, 2007
Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's diseaseMasaaki Waragai, Masaaki Nakai, Jianshe Wei, et al.
Frontiers in Sports and Active Living|May 24, 2024
The effectiveness of video-based exercise training program for people with intellectual disability: a multicenter studyRachel Kwan, Grace Szeto, Ester Ho, et al.
Expert Review of Neurotherapeutics|July 31, 2019
Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease?Gilbert Ho, Yoshiki Takamatsu, Masaaki Waragai, et al.
Nature Medicine|April 27, 2005
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer diseaseMark H Tuszynski, Leon Thal, Mary Pay, et al.
Pageof 3